ClinicalTrials.gg
CompletedNCT06893770Updated Oct 28, 2026

The Effect of Quran Recitation on Quality of Life and Sleep Quality in Patients With Breast Cancer Receiving Chemotherapy

An interventional study of Quran recital and standard treatment and care in Breast Carcinoma, sponsored by Ardahan University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Ardahan University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedFirst site in Turkey (Türkiye)+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.

Enrollment
291st of 321
40 · median 100
Started
2025
with 44 others
No phase
184 of 400
48 open now
Registered
302nd of 400
by date

Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 291st largest by enrollment of the 321 interventional ones that give a count, is one of 45 that started in 2025, is one of 184 with no phase, and was the 302nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 400 studies in Breast Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

To investigate the effect of listening to Qur'an on quality of life and sleep quality in women undergoing chemotherapy for breast cancer. This single-blind randomized controlled trial included 40 women receiving chemotherapy for breast cancer. Participants were assigned using block randomization to either a Qur'an listening group (QLG) or a control group (CG). The QLG listened to Qur'an recitation during chemotherapy sessions, while the CG received standard care only. Data were collected at four time points (T1-T4) using a patient information form, the EORTC QLQ-C30, and the Pittsburgh Sleep Quality Index (PSQI). Analyses were performed using SPSS 26. Across four measurements, the QLG showed significant improvements in all functional domains of the EORTC QLQ-C30 and significant reductions in most symptom domains (p \< .05). No comparable changes were observed in the CG. Overall quality of life increased progressively from T1 to T4 in the QLG, with significant between-group differences emerging at T3 and T4. PSQI total scores decreased significantly in the QLG at T3 and T4 (p \< .001), whereas no clinically meaningful improvement occurred in the CG. At T4, PSQI scores were significantly lower in the QLG than in the CG (p \< .001). Listening to the Qur'an during chemotherapy significantly improves quality of life and sleep quality in women with breast cancer. This non-invasive, low-cost intervention may be integrated into supportive nursing care in oncology settings in accordance with patients' preferences.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

Keywords

  • breast cancer
  • Quran recital
  • life of quality
  • sleep of quality
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having breast cancer
  • Being on chemotherapy
  • Being on a chemotherapy protocol every 21 days
  • Being over the age of 18
  • Not having communication problems
  • Being willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Having a hearing problem
  • Having an ear infection or any condition that prevents hearing
  • Having other types of cancer other than breast cancer
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    experimental group

    Quran listening

    Behavioral: Quran recital

  • Active comparator
    control group

    standard treatment and care

    Other: standard treatment and care

Interventions

  • BehavioralQuran recital

    standard treatment and care

    Also known as: standard treatment and care

  • Otherstandard treatment and care

    standard treatment and care

06

What researchers measure

Primary outcomes

  1. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Version 3.0

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Version 3.0, will be used to assess quality of life. The first 28 items are scored from 1 (not at all) to 4 (very much), while items 29 and 30 are scored from 1 (very poor) to 7 (excellent). Higher scores on the functional scales and Global Health Status/Quality of Life scale indicate better functioning and quality of life, whereas higher scores on the symptom scales and single-item measures indicate greater symptom burden.

    Time frame: From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The scale consists of seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3. The total PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality. A global PSQI score greater than 5 indicates poor sleep quality.

    Time frame: From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.

07

Study locations

1 site
  • Erzurum Technical Universitesi
    Erzurum, Turkey 252500, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data cannot be shared with third parties in order to protect personal data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jan 2026, 9 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 9 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Apr 2026 → Jan 2026 and completion Apr 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 25, 2025
StartActual
Apr 15, 2025
Primary completionActual
Jan 15, 2026was Apr 2026
CompletionActual
Jan 15, 2026was Apr 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 28, 2026
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Erzurum Technical Universitesi · Erzurum, Turkey (Türkiye)
Show 1 removed
  • Erzurum Technical Universitesi · Erzurum, Turkey
Oct 28, 2026
Primary completion
Apr 15, 2026→Jan 15, 2026 (actual)
Oct 28, 2026
Study completion
Apr 15, 2026→Jan 15, 2026 (actual)
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe European OrganizationOrganisation for Research and Treatment of Cancer (EORTC) Quality of Life ScaleQuestionnaire-Core 30 (EORTC QLQ-C30), Version 3.0 (EORTC QLQ C-30)Time frame: From registration to the end of treatment at week 12 → From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
Oct 28, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPittsburgPittsburgh Sleep Quality Index (PSQI)Time frame: From registration to the end of treatment at week 12 → From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
Oct 28, 2026
Title
The Effect of the QuranQuran Recitation on Quality of Life and Sleep Quality of Sleep inin Patients With Breast Cancer Receiving Chemotherapy
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Erzurum Technical Universitesi · Erzurum, Turkey (Türkiye)
    Show 1 removed
    • Erzurum Technical Universitesi · Erzurum, Turkey
    Primary completion Apr 15, 2026→Jan 15, 2026 (now actual)
    Study completion Apr 15, 2026→Jan 15, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe European OrganizationOrganisation for Research and Treatment of Cancer (EORTC) Quality of Life ScaleQuestionnaire-Core 30 (EORTC QLQ-C30), Version 3.0 (EORTC QLQ C-30)Time frame: From registration to the end of treatment at week 12 → From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPittsburgPittsburgh Sleep Quality Index (PSQI)Time frame: From registration to the end of treatment at week 12 → From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
    Title The Effect of the QuranQuran Recitation on Quality of Life and Sleep Quality of Sleep inin Patients With Breast Cancer Receiving Chemotherapy
    + 7 other changes: index terms, responsible party, oversight details, description, design details, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06893770
Lead sponsor
Ardahan University
Collaborators
Erzurum Technical University
Responsible party
Derya Şimşekli (Asst. Prof. Dr., Ardahan University) — Principal investigator
First posted
Mar 25, 2025
Start date
Apr 15, 2025
Primary completion
Jan 15, 2026
Completion
Jan 15, 2026
Last update
Oct 28, 2026

Study contacts

DERYA ŞİMŞEKLİ
principal investigator · Ardahan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion